Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MK-2828 on Rosuvastatin and Furosemide in Healthy Participants
NCT07431866Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of MK-2828 in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity up to 2 weeks. Started Mar 2026; status: completed.
02
Drugs
MK-2828
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07431866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431866.